SG11201906763RA - Pyrrolo [1,2-b] pyridazine derivatives - Google Patents
Pyrrolo [1,2-b] pyridazine derivativesInfo
- Publication number
- SG11201906763RA SG11201906763RA SG11201906763RA SG11201906763RA SG11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA
- Authority
- SG
- Singapore
- Prior art keywords
- gilead sciences
- foster city
- lakeside drive
- lakeside
- international
- Prior art date
Links
- NISJKLIMPQPAQS-UHFFFAOYSA-N pyrrolo[1,2-b]pyridazine Chemical class C1=CC=NN2C=CC=C21 NISJKLIMPQPAQS-UHFFFAOYSA-N 0.000 title abstract 3
- 229940127030 Foster Drugs 0.000 abstract 2
- 229940126656 GS-4224 Drugs 0.000 abstract 2
- 235000015241 bacon Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT omit VIII °nolo HE Imo oimIE (10) International Publication Number WO 2018/152368 Al (51) International Patent Classification: CO7D 487/04 (2006.01) A61K 31/5377 (2006.01) CO7D 519/00 (2006.01) A61K 31/5383 (2006.01) A61K 31/5025 (2006.01) A61K 31/541 (2006.01) A61P 29/00 (2006.01) CO7D 453/00 (2006.01) A61K 31/506 (2006.01) (21) International Application Number: PCT/US2018/018431 (22) International Filing Date: 15 February 2018 (15.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,013 16 February 2017 (16.02.2017) US (71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US). (72) Inventors: BACON, Elizabeth, M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). BRIZGYS, Gediminas; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). CHIN, El- bert; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Fos- ter City, CA 94404 (US). CHOU, Chienhung; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). COTTELL, Jeromy, J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). LINK, John, O.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TAYLOR, James, G.; c/ o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TSE, Winston, C.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). WRIGHT, Nathan, E.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). YANG, Zheng-Yu; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). ZHANG, Jennifer, R.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). ZIPFEL, Sheila, M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). (74) Agent: POLSTER, Philip, B. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) 1-1 (54) Title: PYRROLO [1,2-B] PYRIDAZINE DERIVATIVES (57) : Provided is a compound of Formula (I), wherein the variable groups are defined HN ,Ri herein. R3 141\") H • I 1\r N - R4 N 1-1 0 .- 13 R7 R5 R6 (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460013P | 2017-02-16 | 2017-02-16 | |
| PCT/US2018/018431 WO2018152368A1 (en) | 2017-02-16 | 2018-02-15 | Pyrrolo [1,2-b] pyridazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906763RA true SG11201906763RA (en) | 2019-08-27 |
Family
ID=61563476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906763RA SG11201906763RA (en) | 2017-02-16 | 2018-02-15 | Pyrrolo [1,2-b] pyridazine derivatives |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10336762B2 (en) |
| EP (1) | EP3583105B1 (en) |
| JP (3) | JP6924267B2 (en) |
| KR (1) | KR102337055B1 (en) |
| CN (1) | CN110300754A (en) |
| AR (1) | AR110935A1 (en) |
| AU (2) | AU2018221812B2 (en) |
| CA (1) | CA3050148A1 (en) |
| CL (1) | CL2019002306A1 (en) |
| CO (1) | CO2019008868A2 (en) |
| CR (1) | CR20190373A (en) |
| DK (1) | DK3583105T3 (en) |
| DO (1) | DOP2019000214A (en) |
| EA (1) | EA201991544A1 (en) |
| ES (1) | ES2975767T3 (en) |
| FI (1) | FI3583105T3 (en) |
| HU (1) | HUE065978T2 (en) |
| IL (1) | IL267979B (en) |
| JO (1) | JOP20180011A1 (en) |
| LT (1) | LT3583105T (en) |
| MA (1) | MA47500B1 (en) |
| MX (2) | MX2019009840A (en) |
| PE (1) | PE20191540A1 (en) |
| PH (1) | PH12019550128A1 (en) |
| PL (1) | PL3583105T3 (en) |
| PT (1) | PT3583105T (en) |
| RS (1) | RS65397B1 (en) |
| SA (1) | SA519402462B1 (en) |
| SG (1) | SG11201906763RA (en) |
| SI (1) | SI3583105T1 (en) |
| SM (1) | SMT202400146T1 (en) |
| TW (3) | TWI733982B (en) |
| UA (1) | UA124548C2 (en) |
| UY (1) | UY37608A (en) |
| WO (1) | WO2018152368A1 (en) |
| ZA (1) | ZA201905456B (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CA3076613A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020014068A1 (en) | 2018-07-09 | 2020-01-16 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic heterocyclic compounds |
| TWI842978B (en) * | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
| JP7169429B2 (en) * | 2018-08-13 | 2022-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors |
| KR102659550B1 (en) * | 2018-08-13 | 2024-04-23 | 길리애드 사이언시즈, 인코포레이티드 | Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors |
| JP7623943B2 (en) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | IRAK degraders and their uses |
| CA3133100A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
| CN111821308B (en) * | 2019-04-15 | 2021-10-08 | 中国科学院上海药物研究所 | Application of Leitengshu in the preparation of medicine for the treatment of non-alcoholic fatty liver disease |
| CN110755452B (en) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | Use of stem cells for treating osteoarthritis |
| CN110755451B (en) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | Mesenchymal stem cell composition for treating osteoarthritis and application thereof |
| KR20220145325A (en) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | IRAK disintegrants and uses thereof |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| AU2021278889A1 (en) | 2020-05-29 | 2023-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anthelmintic heterocyclic compounds |
| TW202210483A (en) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Crystalline forms of irak degraders |
| AR124547A1 (en) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | IRAQ DEGRADERS AND THEIR USES |
| MX2023009527A (en) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Irak4 degraders and uses thereof. |
| AR125798A1 (en) | 2021-05-07 | 2023-08-16 | Kymera Therapeutics Inc | CDK2 DEGRADERS AND USES THEREOF |
| DK4367118T3 (en) | 2021-08-18 | 2025-03-24 | Nurix Therapeutics Inc | BIFUNCTIONAL INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ-4 DEGRADER AND SYNTHESIS OF IT |
| UY39995A (en) | 2021-11-01 | 2023-05-15 | Boehringer Ingelheim Vetmedica GmbH | PYRROLOPYRIDAZINE COMPOUNDS AS ANTHELMINTICS |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AR129535A1 (en) | 2022-06-21 | 2024-09-04 | Syngenta Crop Protection Ag | HETEROCYCLIC BICYCLIC CARBOXAMIDE DERIVATIVES MICROBIOCIDES |
| CN120476119A (en) | 2022-10-27 | 2025-08-12 | 先正达农作物保护股份公司 | Microbicidal heterobicyclic dihydrooxadiazine derivatives |
| US20250042906A1 (en) * | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Processes for making irak4 inhibitors |
| CN117849327A (en) * | 2024-03-06 | 2024-04-09 | 军科正源（北京）药物研究有限责任公司 | Methods for detecting a secukinumab-resistant antibody |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511840T1 (en) | 2001-10-09 | 2011-06-15 | Amgen Inc | IMIDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| KR20090049076A (en) | 2006-09-07 | 2009-05-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | Indazole derivatives as interleukin-1 receptor-binding kinase modulators |
| DE102009033208A1 (en) | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | aminopyridine derivatives |
| JP2012254939A (en) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | Oxazole compound |
| MX358682B (en) | 2010-07-13 | 2018-08-31 | Hoffmann La Roche | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators. |
| KR20180099933A (en) | 2010-11-19 | 2018-09-05 | 리간드 파마슈티칼스 인코포레이티드 | Heterocycle amines and uses thereof |
| HRP20161127T1 (en) | 2010-12-20 | 2016-11-18 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US9169260B2 (en) | 2011-03-22 | 2015-10-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| WO2013066729A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| BR112014010938A2 (en) | 2011-11-09 | 2017-05-16 | Cancer Res Tech Ltd | 5- (pyridin-2-yl-amino) -pyrazine-2-carbonitrile compounds and their therapeutic use |
| BR112014017021A8 (en) | 2012-01-10 | 2017-07-04 | Nimbus Iris Inc | irak inhibitors and uses thereof |
| WO2013106612A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| CN104254533B (en) | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | The pyridinyl compounds of thiazole or thiadiazoles substitution as kinase inhibitor |
| CA2878621C (en) | 2012-07-10 | 2020-09-15 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP2015528801A (en) | 2012-07-11 | 2015-10-01 | ニンバス アイリス， インコーポレイテッド | IRAK inhibitors and uses thereof |
| WO2014011911A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US9598440B2 (en) | 2012-10-08 | 2017-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US9586948B2 (en) | 2012-10-08 | 2017-03-07 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| PE20150953A1 (en) | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | HETEROARYL SUBSTITUTE PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS |
| WO2014074657A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| ES2648226T3 (en) | 2012-11-08 | 2017-12-29 | Bristol-Myers Squibb Company | Alkylamide substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and / or IFN |
| SG10201706897TA (en) | 2012-11-08 | 2017-09-28 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alph responses |
| CN104955824B (en) | 2012-11-20 | 2017-09-22 | 豪夫迈·罗氏有限公司 | It is used as the aminopyrimidine compounds of the inhibitor of the EGFR mutant containing T790M |
| BR112015014034A2 (en) | 2013-01-10 | 2017-07-11 | Nimbus Iris Inc | irak inhibitors and uses thereof |
| LT2953952T (en) | 2013-02-07 | 2017-08-25 | Merck Patent Gmbh | Macrocyclic pyridazinone derivatives |
| RS56331B1 (en) | 2013-02-07 | 2017-12-29 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| EP2970334B1 (en) | 2013-03-15 | 2018-05-23 | Biogen MA Inc. | Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases |
| EP3052494B1 (en) | 2013-06-28 | 2018-12-26 | H. Hoffnabb-La Roche Ag | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| WO2015006181A1 (en) | 2013-07-11 | 2015-01-15 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
| CN106232122A (en) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | IRAK inhibitor and its purposes |
| CA2929316C (en) | 2013-11-08 | 2021-12-28 | Takeda Pharmaceutical Company Limited | Pyrazole for the treatment autoimmune disorders |
| TWI667233B (en) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments |
| TW201609693A (en) * | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | Heteroaryl substituted incotinamide compounds |
| CN106068264B (en) | 2014-01-09 | 2019-06-21 | 默克专利有限公司 | Pyrimidine pyrazolyl derivatives and their use as IRAK inhibitors |
| JP2017505337A (en) | 2014-01-10 | 2017-02-16 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Indazole compounds as IRAK4 inhibitors |
| PL3805233T3 (en) | 2014-01-13 | 2024-06-10 | Aurigene Oncology Limited | ENANCIOMERS (R) AND (S) (S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridine -4-yl)oxazole-4-carboxamide as IRAK4 inhibitors for the treatment of malignancy |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| MX2016013668A (en) | 2014-04-22 | 2017-01-20 | Nimbus Iris Inc | Irak inhibitors and uses thereof. |
| CN106456609A (en) | 2014-06-20 | 2017-02-22 | 奥瑞基尼探索技术有限公司 | Substituted indazole compounds as irak4 inhibitors |
| AR101229A1 (en) | 2014-07-18 | 2016-11-30 | Biogen Ma Inc | IRAK4 INHIBITING AGENTS |
| EP3200789B1 (en) | 2014-09-30 | 2019-11-06 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9943516B2 (en) | 2014-09-30 | 2018-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| EP3200788B1 (en) | 2014-09-30 | 2019-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| HUE047586T2 (en) | 2014-11-20 | 2020-04-28 | Merck Patent Gmbh | Heteroaryl compounds as IRAK inhibitors and their applications |
| JO3705B1 (en) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
| KR20170109546A (en) | 2015-02-05 | 2017-09-29 | 메르크 파텐트 게엠베하 | Macrocyclic compounds as IRAK 1/4 inhibitors and their use |
| CA2970550C (en) | 2015-02-06 | 2023-09-19 | Merck Patent Gmbh | Pyridazinone macrocycles as irak inhibitors and uses thereof |
| US10040802B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of IRAK4 activity |
| EP3268367B8 (en) | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| US10040798B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of IRAK4 activity |
| WO2016144848A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of irak4 activity |
| EP3267996B1 (en) | 2015-03-12 | 2020-11-11 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| ES2861351T3 (en) | 2015-04-22 | 2021-10-06 | Rigel Pharmaceuticals Inc | Pyrazole compounds and method of making and using the compounds |
| EP3288558B1 (en) | 2015-04-30 | 2022-05-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| AR105112A1 (en) * | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | AMINOPIRIDINE SUBSTITUTED WITH HETEROARILO COMPOUNDS |
| TW201718571A (en) * | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | Heteroaryl substituted aminopyridine compounds |
| WO2016210037A1 (en) | 2015-06-24 | 2016-12-29 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CU20180006A7 (en) | 2015-07-15 | 2018-06-05 | Aurigene Discovery Tech Ltd | INDAZAOL AND AZAINDAZOL COMPOUNDS AS IRAK-4 INHIBITORS |
| HK1249435A1 (en) | 2015-07-15 | 2018-11-02 | Aurigene Discovery Technologies Limited | Substituted aza compounds as irak-4 inhibitors |
| DK3331877T3 (en) | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | PYRAZOLE PYRIMIDINE DERIVATIVE AND ITS USES |
| CA2993661A1 (en) | 2015-08-04 | 2017-02-09 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
| KR102110573B1 (en) | 2015-08-13 | 2020-05-13 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | IRAK4 inhibitors and uses thereof |
| KR102048719B1 (en) | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | IRAK4 inhibitors and uses thereof |
| JP2018527337A (en) | 2015-08-13 | 2018-09-20 | ファイザー・インク | Bicyclic fused heteroaryl or aryl compounds |
| WO2017033093A1 (en) | 2015-08-27 | 2017-03-02 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators |
| CN108602776B (en) | 2015-09-18 | 2021-12-03 | 默克专利有限公司 | Heteroaryl compounds as IRAK inhibitors and uses thereof |
| MX383707B (en) | 2015-09-18 | 2025-03-14 | Merck Patent Gmbh | HETEROARYL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES (IRAK) AND THEIR USES. |
| GB201518456D0 (en) | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| JP6895439B2 (en) | 2015-12-22 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Pyrazolo [1,5a] pyrimidine derivative as an IRAK4 regulator |
| WO2017108744A1 (en) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Novel substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| EP3405465B1 (en) | 2016-01-20 | 2021-10-13 | Biogen MA Inc. | Irak4 inhibiting agents |
| SI3448848T1 (en) | 2016-04-29 | 2024-01-31 | Bayer Pharma Aktiengesellschaft | Polymorphic form of n-(6-(2-hydroxypropan-2-yl)-2-(2-(methylsulphonyl)ethyl)-2h-indazol-5-yl)-6-(trifluoromethyl)pyridine-2-carboxamide |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017207385A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted 3-methylindazoles, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
| CA3028997A1 (en) | 2016-06-27 | 2018-01-04 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
| US10414753B2 (en) | 2016-10-26 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Amide compounds and method for making and using |
| WO2018083085A1 (en) | 2016-11-02 | 2018-05-11 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
-
2017
- 2017-02-16 JO JOP/2018/0011A patent/JOP20180011A1/en unknown
-
2018
- 2018-02-05 TW TW107103929A patent/TWI733982B/en active
- 2018-02-05 TW TW111148495A patent/TW202340194A/en unknown
- 2018-02-05 TW TW110124807A patent/TWI790674B/en active
- 2018-02-15 US US15/898,095 patent/US10336762B2/en active Active
- 2018-02-15 HU HUE18708796A patent/HUE065978T2/en unknown
- 2018-02-15 IL IL267979A patent/IL267979B/en unknown
- 2018-02-15 EP EP18708796.0A patent/EP3583105B1/en active Active
- 2018-02-15 SM SM20240146T patent/SMT202400146T1/en unknown
- 2018-02-15 CR CR20190373A patent/CR20190373A/en unknown
- 2018-02-15 LT LTEPPCT/US2018/018431T patent/LT3583105T/en unknown
- 2018-02-15 MX MX2019009840A patent/MX2019009840A/en unknown
- 2018-02-15 AU AU2018221812A patent/AU2018221812B2/en active Active
- 2018-02-15 PE PE2019001681A patent/PE20191540A1/en unknown
- 2018-02-15 CA CA3050148A patent/CA3050148A1/en active Pending
- 2018-02-15 KR KR1020197026476A patent/KR102337055B1/en active Active
- 2018-02-15 UA UAA201908592A patent/UA124548C2/en unknown
- 2018-02-15 CN CN201880012452.8A patent/CN110300754A/en active Pending
- 2018-02-15 WO PCT/US2018/018431 patent/WO2018152368A1/en not_active Ceased
- 2018-02-15 JP JP2019543909A patent/JP6924267B2/en active Active
- 2018-02-15 PT PT187087960T patent/PT3583105T/en unknown
- 2018-02-15 PL PL18708796.0T patent/PL3583105T3/en unknown
- 2018-02-15 SI SI201831068T patent/SI3583105T1/en unknown
- 2018-02-15 RS RS20240424A patent/RS65397B1/en unknown
- 2018-02-15 FI FIEP18708796.0T patent/FI3583105T3/en active
- 2018-02-15 ES ES18708796T patent/ES2975767T3/en active Active
- 2018-02-15 SG SG11201906763RA patent/SG11201906763RA/en unknown
- 2018-02-15 MA MA47500A patent/MA47500B1/en unknown
- 2018-02-15 EA EA201991544A patent/EA201991544A1/en unknown
- 2018-02-15 DK DK18708796.0T patent/DK3583105T3/en active
- 2018-02-16 AR ARP180100369A patent/AR110935A1/en unknown
- 2018-02-16 UY UY0001037608A patent/UY37608A/en not_active Application Discontinuation
-
2019
- 2019-07-11 PH PH12019550128A patent/PH12019550128A1/en unknown
- 2019-08-14 CL CL2019002306A patent/CL2019002306A1/en unknown
- 2019-08-15 DO DO2019000214A patent/DOP2019000214A/en unknown
- 2019-08-15 CO CONC2019/0008868A patent/CO2019008868A2/en unknown
- 2019-08-16 MX MX2023010197A patent/MX2023010197A/en unknown
- 2019-08-18 SA SA519402462A patent/SA519402462B1/en unknown
- 2019-08-19 ZA ZA2019/05456A patent/ZA201905456B/en unknown
-
2021
- 2021-07-30 JP JP2021125416A patent/JP2021176902A/en not_active Withdrawn
-
2022
- 2022-09-08 AU AU2022228165A patent/AU2022228165A1/en not_active Abandoned
-
2023
- 2023-04-28 JP JP2023074711A patent/JP2023100791A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201907434RA (en) | Compositions and methods for immunooncology | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201808944QA (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201908159QA (en) | Dual magl and faah inhibitors | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies |